EDSA · Edesa Biotech, Inc. · Documents
$2.77
+0.01 (+0.36%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company’s ability to continue as a going concern is dependent on obtaining additional funding through financings, other strategic activities as well as via grants, to fund the development of its drug candidates. There can be no assurance that the Company will be successful in raising the necessary financing. These conditions indicate the existence of a material uncertainty that may cast substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$26.71M
Shares
9.64M
Volume · Oct 23
18.56K
Avg daily vol (3M)
60.35K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Edesa Biotech, Inc.'s Board raised annual base salaries for Dr. Pardeep Nijhawan to $657,423, Dr. Michael Brooks to $591,681, and Peter Weiler to $525,938, retroactive to July 1, 2026. Dr. Nijhawan will continue receiving 90% of monthly base salary in fully vested restricted share units. | 2026-10-23 | — | |
| 8-K | Edesa Biotech, Inc. said the FDA cleared its IND application for the Phase 2 study of EB06 in vitiligo, enabling U.S. recruitment expansion. Recruitment is underway in Canada, first U.S. sites are expected next quarter, and topline data are anticipated in the fourth quarter 2027. | 2026-10-15 | — | |
| 8-K | — | 2026-08-20 | 2026-08-19 | |
| 8-K | — | 2026-08-13 | — | |
| 10-Q | — | 2026-08-13 | 2026-06-30 | |
| S-3 | — | 2026-07-02 | — | |
| 8-K | — | 2026-06-11 | 2026-06-10 | |
| 8-K | — | 2026-06-05 | — | |
| 8-K | — | 2026-05-29 | 2026-05-27 | |
| 8-K | — | 2026-05-15 | 2026-05-13 | |
| 10-Q | — | 2026-05-14 | 2026-03-31 | |
| 8-K | — | 2026-05-14 | — | |
| DEF 14A | — | 2026-04-03 | 2026-05-27 | |
| ARS | — | 2026-04-03 | 2025-09-30 | |
| DEFA14A | — | 2026-04-03 | — | |
| 8-K | — | 2026-02-24 | — | |
| 8-K | — | 2026-02-13 | — | |
| 10-Q | — | 2026-02-13 | 2025-12-31 | |
| 8-K | — | 2025-12-12 | — | |
| 8-K | — | 2025-12-12 | — | |
| 10-K | — | 2025-12-12 | 2025-09-30 | |
| 8-K | — | 2025-10-28 | — | |
| 8-K | — | 2025-09-30 | — | |
| 8-K | — | 2025-09-09 | — | |
| 10-Q | — | 2025-08-08 | 2025-06-30 | |
| 8-K | — | 2025-08-08 | — | |
| S-3 | — | 2025-07-25 | — | |
| 8-K | — | 2025-05-28 | — | |
| 10-Q | — | 2025-05-14 | 2025-03-31 | |
| 8-K | — | 2025-05-14 | — | |
| 8-K | — | 2025-04-04 | 2025-04-03 | |
| ARS | — | 2025-04-04 | 2024-09-30 | |
| DEFA14A | — | 2025-04-04 | — | |
| DEF 14A | — | 2025-04-04 | 2025-05-28 | |
| S-3 | — | 2025-03-04 | — | |
| 8-K | — | 2025-02-14 | — | |
| 10-Q | — | 2025-02-14 | 2024-12-31 | |
| 8-K | — | 2025-02-13 | 2025-02-12 | |
| 10-K/A | — | 2024-12-20 | 2024-09-30 | |
| 10-K | — | 2024-12-13 | 2024-09-30 | |
| 8-K | — | 2024-12-13 | — | |
| 8-K | — | 2024-10-31 | 2024-10-30 | |
| 8-K | — | 2024-10-04 | 2024-10-03 | |
| 8-K | — | 2024-08-09 | — | |
| 10-Q | — | 2024-08-09 | 2024-06-30 | |
| 8-K | — | 2024-06-24 | — | |
| 8-K | — | 2024-05-30 | — | |
| 10-Q | — | 2024-05-10 | 2024-03-31 | |
| 8-K | — | 2024-05-10 | — | |
| DEFA14A | — | 2024-04-05 | — |
Showing 1–50 of 126 filings